FarmaKology Newsletter - Issue #23
Today's Startup
Carbiotix
Carbiotix was founded in 2014 as a spin-off company from the Department of Biotechnology at Lund University, Sweden, the largest university in the Nordic Region and a global top 100 university. The company’s soluble fiber ingredient AXOS was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US in 2015. In 2016, an Irish-based company called Pure Fiber Limited was formed to commercialize the AXOS technology.
News
ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company's recent program progress as well as a white paper analysis of Biogen's October 22, 2019 decision to submit its amyloid-beta (Aβ)-targeting drug candidate, aducanumab for Alzheimer's disease to the U.S. Food and Drug administration in early 2020.
IsoPlexis Receives $2 Million National Cancer Institute Grant to Target the Functional Pathways in Rare Cancer Cells that Drive Resistance
IsoPlexis, the leading life sciences company in the single-cell proteomics space, announced today that it has received $2 million in grant funding from the National Cancer Institute's Small Business Innovation Research Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.
AbbVie draws favorable rating for its rheumatism drug in Europe
AbbVie Korea said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Rinvoq (Ingredient: upadacitinib), a once-daily selective and reversible Janus kinase (JAK) inhibitor treating rheumatoid arthritis.
Daewoong releases trial data on gastroesophageal reflux disease drug
Daewoong Pharmaceutical said that it has presented its phase 1 multiracial clinical trial for DWP14012, a gastroesophageal reflux disease (GERD) treatment candidate, during the United European Gastroenterology held in Barcelona, Spain.
Research & Study
Leading Doctor Says Magnesium Deficiencies Are One Of The Most Overlooked Problems In Conventional Medicine
Study finds doctor-pharmacist partnership significantly reduces patient harm
Vit D deficiency linked to poor muscle function
Podcast
Job Opportunities
Medical Representative
Pharmacy Technician
clinical pharmacist
Pharmacist
Upcoming Events
International Conference on Traditional Medicine and Ethnomedical Research
Arab Pediatrics Conference Abu Dhabi
Rural Medicine Australia
Video
